Cytosorbents Corporation (CTSO) Financials
CTSO Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 53.3 million | 30.0 million |
2023-09-30 | 47.6 million | 29.1 million |
2023-06-30 | 52.4 million | 28.4 million |
2023-03-31 | 57.5 million | 28.5 million |
CTSO Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -6.5 million | 1.1 million |
2023-09-30 | -5.5 million | 1.4 million |
2023-06-30 | -6.7 million | 214542 |
2023-03-31 | -3.8 million | 1.1 million |
CTSO Net Income
No data available :(
CTSO Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 14.1 million | - | 13.3 million |
2023-09-30 | 8.4 million | - | 13.0 million |
2023-06-30 | 13.2 million | - | 13.1 million |
2023-03-31 | 19.0 million | - | 13.2 million |
CTSO Shares Outstanding
CTSO Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 135922 | 4.1 million | 10.6 million | -1.3 million |
2023-09-30 | 257715 | 3.7 million | 9.2 million | - |
2023-06-30 | 209448 | 3.7 million | 8.9 million | 38000 |
2023-03-31 | 682884 | 4.2 million | 9.1 million | 55000 |
CTSO Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 8.7 million | 3.4 million |
2023-09-30 | 7.8 million | 3.2 million |
2023-06-30 | 8.1 million | 3.4 million |
2023-03-31 | 7.9 million | 4.0 million |
CTSO
Price: $0.88
52 week price:
Earnings Per Share: -0.64 USD
P/E Ratio: -1.92
Exchange: NCM
Sector: Healthcare
Industry: Medical Devices
Volume: 305200
Ebitda: -2.1 millionMarket Capitalization: 54.1 million